皓元转债

Search documents
上海皓元医药股份有限公司可转债转股结果暨股份变动公告
Shang Hai Zheng Quan Bao· 2025-10-09 20:36
证券代码:688131 证券简称:皓元医药 公告编号:2025-113 转债代码:118051 转债简称:皓元转债 上海皓元医药股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ● 累计转股情况:上海皓元医药股份有限公司(以下简称"公司")向不特定对象发行可转换公司债 券"皓元转债"自2025年6月4日开始转股。截至2025年9月30日,累计已有人民币464,000元"皓元转债"转 换为公司股票,累计转股数量为11,412股,占"皓元转债"转股前公司已发行股份总额的0.0054%。 ● 未转股可转债情况:截至2025年9月30日,"皓元转债"尚未转股的金额为821,886,000元,占"皓元转 债"发行总量的99.94%。 ● 本季度转股情况:自2025年7月1日至2025年9月30日期间,"皓元转债"共有人民币414,000元转换为公 司股票,转股数量为10,190股,占"皓元转债"转股前公司已发行股份总额的0.0048%。 一、可转债发行上市概况 经中国证券监督 ...
上海皓元医药股份有限公司关于实施2025年半年度权益分派时“皓元转债”停止转股的提示性公告
Shang Hai Zheng Quan Bao· 2025-09-29 21:37
转债代码:118051 转债简称:皓元转债 上海皓元医药股份有限公司 关于实施2025年半年度权益分派时"皓元转债" 停止转股的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 证券停复牌情况:适用 证券代码:688131 证券简称:皓元医药 公告编号:2025-112 本次权益分配方案实施后,公司将根据《上海皓元医药向不特定对象发行可转换公司债券募集说明书》 (以下简称"《募集说明书》")的发行条款及相关规定,对"皓元转债"当期转股价格进行调整。 二、本次权益分派方案实施时停止转股的安排 1、公司将于2025年10月14日在上海证券交易所网站(www.sse.com.cn)披露权益分派实施公告和"皓元 转债"转股价格调整公告。 2、自2025年10月13日至权益分派股权登记日期间,"皓元转债"将停止转股,权益分派股权登记日后的 第一个交易日起"皓元转债"恢复转股,欲享受公司2025年半年度权益分派的可转债持有人可在2025年10 月10日(含2025年10月10日)之前进行转股。 三、其他 因实 ...
中证转债指数高开0.15%
Ge Long Hui· 2025-08-07 02:06
Group 1 - The convertible bonds of Weicai and Ou22 increased by over 4% [1] - The convertible bond of Rundar rose by over 3% [1] - The convertible bonds of Hongwei and Youzu fell by over 2% [1] - The convertible bonds of Haoyuan and Wenkai declined by over 1% [1]
上海皓元医药股份有限公司 关于2023年限制性股票激励计划 第二类限制性股票第二个归属期归属结果暨股份上市公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-08-01 23:13
Core Points - The company announced the results of the second vesting period for its 2023 restricted stock incentive plan, with 527,660 shares to be listed on August 6, 2025, representing 0.25% of the company's total share capital before vesting [2][3][4] Group 1: Stock Incentive Plan Details - The stock listing type is for equity incentive shares, with a total of 527,660 shares to be listed [2][3] - The decision-making process for the stock vesting was approved by the board and supervisory committee on June 26, 2023, and the plan was publicly disclosed on June 27, 2023 [4][5][6] - The number of individuals eligible for the stock vesting is 97, with the actual number of shares vesting being 527,660 [12][13] Group 2: Stock Listing and Capital Changes - The listing date for the vested shares is set for August 6, 2025, and the total share capital will increase from 211,571,033 shares to 212,098,693 shares [14][17] - The company received a total of RMB 11,904,009.60 from the 97 participants in the stock incentive plan, which includes an increase in share capital of RMB 527,660 [17] - The impact of the new shares on the company's financial report is minimal, with the diluted earnings per share remaining stable [18] Group 3: Convertible Bond Adjustments - The company announced an adjustment to the conversion price of its convertible bonds ("Hao Yuan Convertible Bonds") due to the completion of the stock vesting [19][20] - The conversion price was adjusted from RMB 40.59 to RMB 40.55 per share, effective from August 5, 2025 [23][26] - The adjustment was made in accordance with the company's regulations and relevant laws, ensuring the protection of bondholders' rights [24][25]
中证转债指数收跌0.08%
Shang Hai Zheng Quan Bao· 2025-07-30 08:45
Group 1 - The China Convertible Bond Index closed down 0.08% at 460.63 points on July 30 [1] - Qizheng Convertible Bond increased by 12.40%, Sheyan Convertible Bond rose by 8.14%, and Punaite Convertible Bond gained 6.03% [1] - Tongguang Convertible Bond fell by 8.82%, Haoyuan Convertible Bond decreased by 7.28%, and Bojun Convertible Bond dropped by 6.04% [1]
中证转债指数高开0.08%。华医转债涨超9%,天23转债、华宏转债、平煤转债涨超2%;大禹转债、皓元转债、博俊转债、博瑞转债、汇成转债等跌超1%。
news flash· 2025-07-30 01:35
Group 1 - The China Securities Convertible Bond Index opened up by 0.08% [1] - Hua Yi Convertible Bond increased by over 9%, while Tian 23, Hua Hong, and Pingmei Convertible Bonds rose by over 2% [1] - Dayu, Haoyuan, Bojun, Borui, and Huicheng Convertible Bonds fell by over 1% [1]
上海皓元医药股份有限公司关于不提前赎回“皓元转债”的公告
Shang Hai Zheng Quan Bao· 2025-07-29 17:44
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:688131 证券简称:皓元医药 公告编号:2025-096 转债代码:118051 转债简称:皓元转债 上海皓元医药股份有限公司关于不提前赎回"皓元转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示: (三)可转债转股期限 根据有关规定和《募集说明书》的约定,公司本次发行的"皓元转债"自2025年6月4日起可转换为公司股 票。转股期间为2025年6月4日至2030年11月27日,初始转股价格为40.73元/股。 (四)可转债转股价格的历次调整情况 ● 自2025年7月8日至2025年7月29日期间,上海皓元医药股份有限公司(以下简称"公司"或"皓元医 药")股票满足在连续三十个交易日中有十五个交易日的收盘价不低于"皓元转债"当期转股价格(40.59 元/股)的130%(含130%,即52.77元/股),已触发《上海皓元医药股份有限公司向不特定对象发行可 转换公司债券募集说明书》(以下简称"《募集说明书》")中规定的有条件赎回条款。 ● 公 ...
30日投资提示:天23转债提议下修
集思录· 2025-07-29 13:50
Group 1 - The board of Tian23 Convertible Bond proposed a down adjustment [1] - A shareholder of Aotewei plans to reduce their stake by no more than 1.37% [1] - Meijin Energy's largest shareholder, Meijin Energy Group, has pledged all of its shares, totaling 35.32 million shares, which accounts for 2.15% of its holdings and 0.80% of the company's total share capital [1] - As of July 28, 2025, Meijin Group's cumulative pledged shares represent 100% of its total holdings [1] - Haoyuan Convertible Bond and Huicheng Convertible Bond will not be forcibly redeemed [1] - Yinwei Convertible Bond and Guowei Convertible Bond will not undergo down adjustment [1]
皓元医药: 上海皓元医药股份有限公司关于控股股东可转债持有比例变动达到10%的公告
Zheng Quan Zhi Xing· 2025-07-14 16:28
Group 1 - The company issued 8,223,500 convertible bonds with a total value of 82,235,000 RMB, each with a face value of 100 RMB, and a maturity of 6 years [1][2] - The controlling shareholder, Shanghai Anxu Information Technology Co., Ltd., acquired 2,653,870 bonds, representing 32.27% of the total issuance [2] - From July 8 to July 14, 2025, the controlling shareholder reduced its holdings by 925,460 bonds, bringing the total holdings down to 1,728,410 bonds, which is 21.02% of the total issuance [2]
股市必读:皓元医药(688131)7月4日主力资金净流入2065.55万元,占总成交额4.92%
Sou Hu Cai Jing· 2025-07-06 19:20
Group 1 - The stock price of Haoyuan Pharmaceutical (688131) closed at 51.89 yuan on July 4, 2025, with an increase of 3.26% and a trading volume of 81,700 shares, resulting in a transaction amount of 420 million yuan [1] - On July 4, the net inflow of main funds was 20.6555 million yuan, accounting for 4.92% of the total transaction amount, while retail investors had a net outflow of 38.5298 million yuan, accounting for 9.18% [1][4] - The company announced a share repurchase and cancellation of 47,725 shares due to the failure of a performance commitment by a related party, resulting in a change in total share capital from 211,609,573 shares to 211,561,848 shares [1][4] Group 2 - The convertible bond "Haoyuan Convertible Bond" will have its conversion price adjusted from 40.58 yuan to 40.59 yuan per share, effective from July 8, 2025, following the share repurchase [2] - The bond will be suspended from conversion starting July 7, 2025, and will resume on July 8, 2025 [2][4] - The company issued 822.35 million yuan of convertible bonds with a maturity of six years, with an initial conversion price of 40.73 yuan per share [2]